UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 97

Sortiert nach

The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives

Frontiers in cellular neuroscience, 2022-05, Vol.16, p.903729-903729

2022

Volltextzugriff (PDF)

The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome

Scientific reports, 2021-03, Vol.11 (1), p.6300-6300, Article 6300

2021

Volltextzugriff (PDF)

Fatty Acids: A Safe Tool for Improving Neurodevelopmental Alterations in Down Syndrome?

Nutrients, 2022-07, Vol.14 (14), p.2880

2022

Volltextzugriff (PDF)

Brain circuit pathology in Down syndrome: from neurons to neural networks

Reviews in the neurosciences, 2023-06, Vol.34 (4), p.365

Bartesaghi, Renata

2023

Volltextzugriff (PDF)

HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder

Human molecular genetics, 2016-09, Vol.25 (18), p.3887-3907

2016

Volltextzugriff (PDF)

A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS

Experimental neurology, 2017-12, Vol.298 (Pt A), p.79-96

2017

Volltextzugriff (PDF)

Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3β signaling

Neurobiology of disease, 2014-10, Vol.70 (100), p.53-68

2014

Volltextzugriff (PDF)

Timing of therapies for Down syndrome: the sooner, the better

Frontiers in behavioral neuroscience, 2015-10, Vol.9, p.265-265

2015

Volltextzugriff (PDF)

Obstructive sleep apneas naturally occur in mice during REM sleep and are highly prevalent in a mouse model of Down syndrome

Neurobiology of disease, 2021-11, Vol.159, p.105508-105508, Article 105508

2021

Volltextzugriff (PDF)

Inhibition of GSK3β rescues hippocampal development and learning in a mouse model of CDKL5 disorder

Neurobiology of disease, 2015-10, Vol.82, p.298-310

2015

Volltextzugriff (PDF)

Corrigendum to “APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome” [Neurobiology of Disease 67 (2014) 24–36]

Neurobiology of disease, 2020-05, Vol.138, p.104769-104769, Article 104769

2020

Volltextzugriff (PDF)

Neonatal treatment with cyclosporine A restores neurogenesis and spinogenesis in the Ts65Dn model of Down syndrome

Neurobiology of disease, 2019-09, Vol.129, p.44-55

2019

Volltextzugriff (PDF)

Increased hippocampal epigenetic age in the Ts65Dn mouse model of Down Syndrome

Frontiers in aging neuroscience, 2024-05, Vol.16, p.1401109-1401109

2024

Volltextzugriff (PDF)

The Amyloid Precursor Protein (APP) Triplicated Gene Impairs Neuronal Precursor Differentiation and Neurite Development through Two Different Domains in the Ts65Dn Mouse Model for Down Syndrome

The Journal of biological chemistry, 2013-07, Vol.288 (29), p.20817-20829

2013

Volltextzugriff (PDF)

Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome

Neurobiology of disease, 2020-07, Vol.140, p.104874-104874, Article 104874

2020

Volltextzugriff (PDF)

Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice

Neurobiology of disease, 2015-02, Vol.74, p.204-218

2015

Volltextzugriff (PDF)

Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome

Neurobiology of disease, 2015-10, Vol.82, p.385-396

2015

Volltextzugriff (PDF)

Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model

Brain (London, England : 1878), 2014-02, Vol.137 (2), p.380-401

2014

Volltextzugriff (PDF)

Neuroanatomical alterations and synaptic plasticity impairment in the perirhinal cortex of the Ts65Dn mouse model of Down syndrome

Neurobiology of disease, 2017-10, Vol.106, p.89-100

2017

Volltextzugriff (PDF)

Impaired Brain Mitochondrial Bioenergetics in the Ts65Dn Mouse Model of Down Syndrome Is Restored by Neonatal Treatment with the Polyphenol 7,8-Dihydroxyflavone

Antioxidants, 2021-12, Vol.11 (1), p.62

2021

Volltextzugriff (PDF)

APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome

Neurobiology of disease, 2014-07, Vol.67, p.24-36

2014

Volltextzugriff (PDF)

Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of down syndrome

PloS one, 2013-04, Vol.8 (4), p.e61689-e61689

2013

Volltextzugriff (PDF)

Cell Cycle Elongation Impairs Proliferation of Cerebellar Granule Cell Precursors in the Ts65Dn Mouse, an Animal Model for Down Syndrome

Brain pathology (Zurich, Switzerland), 2009-04, Vol.19 (2), p.224-237

2009

Volltextzugriff (PDF)

Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome

Neurobiology of disease, 2017-07, Vol.103, p.11-23

2017

Volltextzugriff (PDF)

New Perspectives for the Rescue of Cognitive Disability in Down Syndrome

The Journal of neuroscience, 2015-10, Vol.35 (41), p.13843-13852

2015

Volltextzugriff (PDF)

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(91)

Publikationsform

Artikel
(96)
Buchkapitel
(1)

Sprache

Englisch
(97)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives

The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome

Fatty Acids: A Safe Tool for Improving Neurodevelopmental Alterations in Down Syndrome?

Brain circuit pathology in Down syndrome: from neurons to neural networks

HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder

A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS

Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3β signaling

Timing of therapies for Down syndrome: the sooner, the better

Obstructive sleep apneas naturally occur in mice during REM sleep and are highly prevalent in a mouse model of Down syndrome

Inhibition of GSK3β rescues hippocampal development and learning in a mouse model of CDKL5 disorder

Corrigendum to “APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome” [Neurobiology of Disease 67 (2014) 24–36]

Neonatal treatment with cyclosporine A restores neurogenesis and spinogenesis in the Ts65Dn model of Down syndrome

Increased hippocampal epigenetic age in the Ts65Dn mouse model of Down Syndrome

The Amyloid Precursor Protein (APP) Triplicated Gene Impairs Neuronal Precursor Differentiation and Neurite Development through Two Different Domains in the Ts65Dn Mouse Model for Down Syndrome

Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome

Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice

Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome

Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model

Neuroanatomical alterations and synaptic plasticity impairment in the perirhinal cortex of the Ts65Dn mouse model of Down syndrome

Impaired Brain Mitochondrial Bioenergetics in the Ts65Dn Mouse Model of Down Syndrome Is Restored by Neonatal Treatment with the Polyphenol 7,8-Dihydroxyflavone

APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome

Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of down syndrome

Cell Cycle Elongation Impairs Proliferation of Cerebellar Granule Cell Precursors in the Ts65Dn Mouse, an Animal Model for Down Syndrome

Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome

New Perspectives for the Rescue of Cognitive Disability in Down Syndrome

Suchergebnisse filtern